Loading organizations...
Key people at T.Rx Capital.
T.Rx Capital is a venture capital firm, strategically investing in the healthcare sector, particularly where biology and technology converge. It targets entities developing therapeutics and digital health products. The firm backs companies building scalable platforms, aiming to reshape disease treatment through its investments.
Established in 2023, T.Rx Capital was co-founded by Michael Langer, leveraging the deep biotech experience of his father, Robert Langer. The firm's inception was driven by the transformative potential of merging advanced technology with biological sciences to foster innovation in healthcare. This leadership provides an advantage in identifying promising ventures.
T.Rx Capital partners with entrepreneurs and early-stage companies dedicated to advancing healthcare through scientific and technological breakthroughs. Its vision is to define the future of healthcare by cultivating ventures where technology and biology create lasting impact on patient care. The firm empowers these companies to establish transformative platforms for progress.
Key people at T.Rx Capital.
T.Rx Capital is a Boston- and San Francisco-based venture capital firm focused on early-stage investments in healthcare companies at the intersection of biology and technology. Its mission is to back visionary founders building breakthrough innovations in biotechnology, techbio, and tech-enabled healthcare services, providing capital, strategic support, and a strong network to help these companies scale from seed through Series B stages. The firm targets sectors including biotechnology, digital therapeutics, and medical technology, aiming to reshape disease treatment through scalable platforms that combine biology and technology[2][4][6].
Founded in 2023 by Michael Langer, Corey McCann, and Kwesi Frimpong-Boateng, T.Rx Capital leverages the deep operating and investing expertise of its leadership team, including ties to the biotech pioneer Dr. Robert Langer, who serves as Executive Chairman. The firm closed its inaugural Fund I at $77.5 million, with backing from institutional investors, family offices, and prominent biotech founders. The founders bring backgrounds from Pear Therapeutics, Polaris Partners, and Eli Lilly, combining scientific rigor with execution-focused support to help startups create durable value from inception[2][4][5].
T.Rx Capital rides the growing trend of convergence between biology and technology, a sector poised for transformative breakthroughs in disease treatment and healthcare delivery. The timing is favorable due to recovering exit markets and increasing investor interest in biotech and digital health innovation. By focusing on early-stage companies that blend tech and biology, T.Rx Capital is positioned to influence the next wave of category-defining healthcare startups, helping to accelerate innovation in therapeutics, diagnostics, and tech-enabled healthcare services[2][4][7].
Looking ahead, T.Rx Capital aims to build a diversified portfolio of 10 to 15 companies, continuing to invest in bold startups that leverage technology to revolutionize biology and healthcare. Trends such as digital therapeutics, personalized medicine, and AI-driven biotech will likely shape their investment focus. With its strong scientific advisory board and operational expertise, T.Rx Capital is well-positioned to deepen its influence in the healthcare innovation ecosystem, potentially driving new standards in how diseases are treated and managed globally[2][4][7].
In summary, T.Rx Capital stands out as a venture firm uniquely blending deep biotech expertise with technology-driven healthcare innovation, supporting early-stage companies that have the potential to transform medicine and improve patient outcomes.
